Do Medibank shares now represent a buying opportunity?

Medibank has said it will not meet any ransom demands, which has seen the hackers begin to publish sensitive stolen customer data.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Medibank shares have fallen 21% since the company's October data breach
  • Stake reports its customers have seen this as a buying opportunity
  • At the current share price, the ASX 200 health insurer pays a trailing dividend yield of 4.8%

Medibank Private Ltd (ASX: MPL) shares have come under considerable selling pressure following the company's massive data breach last month.

On 26 October, when the S&P/ASX 200 Index (ASX: XJO) private health insurer emerged from a multi-day trading halt, shares plunged 18.1% over the day.

A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.

Image source: Getty Images

What's going on with the data breach?

In a nutshell, hackers — apparently Russian-based — stole sensitive data from 9.7 million of Medibank's former and current clients. That data includes customer names, dates of birth, addresses, phone numbers and email addresses.

The cybercriminals also accessed health claims data for approximately 480,000 customers.

Earlier this week, the healthcare stock said it would not cave into any ransom demands from the hackers, which saw Medibank shares rise on the day.

The hackers responded by threatening to publish all of the customer data on the dark web. A threat they began to follow through with yesterday.

Do Medibank shares now represent a buying opportunity?

Medibank shares remain down 21% since the company exited its trading halt on 26 October.

So, is it a buying opportunity?

Eliot Hastie, markets analyst at Australian brokerage platform Stake, said that for the platform's clients, the answer looks to be yes.

"Stake customers have seen this as a buying opportunity, with a 1,426% increase in buys last month, suggesting that many are still positive about Medibank's long-term outlook," he said. "In fact, Medibank saw the biggest change from sales to buys of all Australian stocks in October when compared to September."

According to Hastie:

Cyber security incidents often cause an instant hard shock to a share price, but strong companies have generally been able to recover over the long term. That said, there's no way of knowing the true consequences of Medibank's current breach.

There has been a suggestion of a class action lawsuit, which could affect the share price over a longer period, but this situation is still developing, and its impact is yet to be seen.

If you're considering investing in Medibank shares, there's also the potential income stream to keep in mind.

As at yesterday's closing share price of $2.77, Medibank pays a trailing dividend yield of 4.8%, fully franked.

How have Medibank shares been tracking in 2022?

The Medibank share price was in the green, significantly outperforming the ASX 200 over the calendar year, right up until the big selloff on 26 October. That selling now sees Medibank shares down 19% in 2022, compared to an 8% loss posted by the benchmark index.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor with stethoscope around neck shrugging.
Earnings Results

CSL reports on 18 August. Can the healthcare giant arrest the slide?

A make-or-break result for Australia's fallen biotech giant.

Read more »

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Regis Healthcare acquires Royal Freemasons' Victorian home care business

Regis Healthcare has announced the acquisition of Royal Freemasons’ home care business, expanding its client base and annualised home care…

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

CSL vs Telix shares: Which is the better buy?

One valuation immediately caught my attention, while the other requires considerably more confidence in future growth.

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Healthcare Shares

This ASX healthcare stock trades at its cheapest multiple in a decade

A quality business at a decade-low multiple. What gives?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

CSL shares bounced in July after a brutal year: What's next?

Can CSL sustain July's rebound when it reports FY2026 results this month.

Read more »

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »